A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy.

Trial Profile

A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms ZACTHYF
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 07 Oct 2016 Planned End Date changed from 1 May 2017 to 1 Dec 2019.
    • 24 May 2016 Status changed from completed to active, no longer recruiting.
    • 24 May 2016 Planned End Date changed from 1 Dec 2012 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top